ID：S03
Therapeutic Strategy：Anti-TNF agents
Synonyms：Tumor necrosis factor
Related Targets：macrophages; T cells; dendritic cells; fibroblasts; fat cells
Related Drugs：infliximab; adalimumab; golimumab; certolizumab pegol
Mechanism：TNF is produced by various immune and non-immune cells in the inflamed gut of patients with IBD, including macrophages, T cells, dendritic cells, fibroblasts and fat cells.This cytokine has pleiotropic effects in the bowel wall: it induces neoangiogenesis; activates macrophages to produce proinflammatory cytokines; favours Paneth cell death via necroptosis; augments apoptosis of intestinal epithelial cells42; regulates T-cell apoptosis; and reduces production of tissue inhibitor of matrix metalloproteinases (MMPs) by fibroblasts to mediate tissue injury via activated MMPs.

Related Literature

Infliximab, azathioprine, or combination therapy for Crohn's disease.
📅 Publication Date: 2025-07-23
📖 Source: The New England journal of medicine
# PMID: 20393175
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS: In this randomized, double…
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology
# PMID: 21723220
BACKGROUND & AIMS: In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, patients with ulcerative colitis treated with infliximab were more likely than those given placebo to …
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology
# PMID: 22062358
BACKGROUND & AIMS: Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-alpha. Its efficacy as maintenance therapy for patients with ulcerative c…
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
📅 Publication Date: 2025-07-23
📖 Source: Gastroenterology
# PMID: 23770005
BACKGROUND & AIMS: Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-alpha (TNFalpha), was evaluated as maintenance therapy in TNFalpha antagonist…
Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
📅 Publication Date: 2025-07-23
📖 Source: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
# PMID: 27704400
Certolizumab pegol (Cimzia((R))) is a subcutaneously administered polyethylene glycolylated (PEGylated) antigen-binding fragment of a recombinant human monoclonal antibody that se…